LIGAND PHARMACEUTICALS INC - Common Stock (LGND)

Historical Holders from Q1 2014 to Q1 2025

Symbol
LGND on Nasdaq
CUSIP
53220K504
Type / Class
Equity / Common Stock
Shares outstanding
18.8M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
18.2M
Holdings value
$1.95B
% of all portfolios
0.003%
Grand Portfolio weight change
+0%
Number of holders
254
Number of buys
137
Number of sells
-80
Average Value change %
0%
Average buys %
+0%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of LIGAND PHARMACEUTICALS INC - Common Stock (LGND)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 15.6% $318M 2.95M BlackRock, Inc. Dec 31, 2024
JANUS HENDERSON GROUP PLC 5.4% $110M 1.02M JANUS HENDERSON GROUP PLC Dec 31, 2024

Institutional Holders of LIGAND PHARMACEUTICALS INC - Common Stock (LGND)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 1.34M $140M +$3.18M $105.14 29
2024 Q4 18.2M $1.95B +$20.8M $107.15 254
2024 Q3 18.1M $1.81B +$73.3M $100.09 238
2024 Q2 17.3M $1.45B +$88M $84.26 230
2024 Q1 16.4M $1.2B +$23.5M $73.10 220
2023 Q4 16.1M $1.15B +$29.9M $71.42 206
2023 Q3 15.6M $937M +$5.47M $59.92 191
2023 Q2 15.3M $1.1B +$33M $72.10 199
2023 Q1 14.8M $1.09B +$25.2M $73.56 206
2022 Q4 14.5M $972M -$14.7M $66.80 189
2022 Q3 13.9M $1.2B -$2.61M $86.11 191
2022 Q2 14.9M $1.33B -$64.9M $89.22 181
2022 Q1 15.6M $1.75B -$90.4M $112.49 187
2021 Q4 16.2M $2.51B -$20.6M $154.46 210
2021 Q3 16.4M $2.29B +$68.6M $139.32 200
2021 Q2 15.9M $2.09B +$57.1M $131.19 208
2021 Q1 15.4M $2.35B -$956M $152.45 217
2020 Q4 22.4M $2.22B -$5.88M $99.45 226
2020 Q3 22.7M $2.16B +$67.3M $95.32 245
2020 Q2 22M $2.47B -$51.4M $111.85 250
2020 Q1 22.8M $1.66B -$15.1M $72.72 248
2019 Q4 22.5M $2.34B -$63.5M $104.29 250
2019 Q3 23.2M $2.31B -$159M $99.54 261
2019 Q2 24.6M $2.81B -$39.3M $114.15 291
2019 Q1 25.4M $3.2B -$112M $125.71 314
2018 Q4 26.7M $3.63B +$256M $135.70 345
2018 Q3 24.2M $6.64B -$318M $274.49 369
2018 Q2 25.5M $5.27B +$238M $207.17 336
2018 Q1 24.3M $4B +$70.5M $165.16 317
2017 Q4 24.7M $3.38B -$25.2M $136.93 292
2017 Q3 24.6M $3.35B -$39.9M $136.15 284
2017 Q2 24.5M $2.97B +$95.4M $121.40 257
2017 Q1 24.6M $2.6B +$242M $105.84 246
2016 Q4 24.8M $2.52B +$4.61M $101.61 262
2016 Q3 24.3M $2.48B +$61.6M $102.06 253
2016 Q2 24.7M $2.94B -$22.7M $119.27 260
2016 Q1 24.2M $2.6B +$161M $107.09 243
2015 Q4 23.2M $2.51B +$43M $108.42 230
2015 Q3 22.8M $1.95B -$32.3M $85.65 200
2015 Q2 21.3M $2.15B -$50.9M $100.90 211
2015 Q1 22M $1.69B +$80.1M $77.11 180
2014 Q4 21.6M $1.15B -$777K $53.21 177
2014 Q3 21.6M $1.02B +$40.5M $46.99 172
2014 Q2 20.1M $1.25B -$48.4K $62.29 189
2014 Q1 20.8M $1.4B +$25.8M $67.26 181